Why did Regeneron's total revenue decline despite strong Dupixent growth?

The decline was driven by EYLEA. Combined EYLEA HD and EYLEA U.S. net sales fell 26% to $1.04 billion because legacy EYLEA lost volume to biosimilars and compounded bevacizumab, patients transitioned to EYLEA HD, and net selling prices fell. Wholesaler inventory was also lower at quarter end. Sanofi collaboration revenue rose 30%, but this did not fully offset the EYLEA decline, leaving total revenue down 4%.

Why did non-GAAP EPS fall while GAAP EPS rose?

GAAP net income benefited from a $140 million net unrealized gain on equity securities, compared with a $196 million unrealized loss in Q1 2024. Non-GAAP results exclude these investment gains, so the swing from a year-earlier loss to a gain boosted GAAP earnings while non-GAAP earnings declined 17% in net income terms, from $1.12 billion to $928 million.

How serious are the FDA setbacks for EYLEA HD?

The pre-filled syringe CRL reportedly did not raise safety, efficacy, device usability, labeling, or pre-approval inspection concerns, and management believes the key issue involves a third-party component supplier that is responding quickly. The extended dosing CRL is more limiting, since the FDA said the data do not support intervals beyond every 16 weeks, and management is still evaluating that decision. Investors should watch resubmission timing and whether the monthly dosing and RVO sBLA, with an August 19, 2025 target action date, proceeds on schedule.

What is Regeneron's capital allocation strategy?

Management is prioritizing internal R&D and commercial investment, opportunistic share repurchases, and a dividend that was initiated in 2025. Q1 buybacks totaled $1.05 billion, with $3.87 billion remaining under authorizations as of March 31, 2025. The company also announced more than $7 billion in New York and North Carolina infrastructure and manufacturing investments, including a 10-year Fujifilm agreement expected to nearly double its large-scale U.S. manufacturing capacity.

What should investors watch for the rest of 2025?

Key catalysts include the June 20 Dupixent bullous pemphigoid action date, the July 10 linvoseltamab and July 30 odronextamab decisions, the August 19 EYLEA HD RVO and monthly dosing decision, and resolution of the EYLEA HD pre-filled syringe CRL. Management also expects pivotal or proof-of-concept data across immunology, oncology, hematology, internal medicine, and rare diseases later in 2025. Gross margin pressure from inventory write-offs and the lower guidance range are also important to monitor.

REGN 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.

Regeneron reported first quarter 2025 results on April 29, 2025, with total revenues of $3.03 billion^a (down 4% year over year) and GAAP diluted EPS of $7.27 (up 16%), while non-GAAP diluted EPS fell 14% to $8.22.

The top-line decline was driven by EYLEA, where combined EYLEA HD and EYLEA U.S. net sales fell 26% to $1.04 billion^b as legacy EYLEA lost volume to biosimilars, compounded bevacizumab, and the transition to EYLEA HD. EYLEA HD U.S. sales grew 54% to $307 million, a bright spot, but not enough to offset the legacy decline. Partly offsetting this, Sanofi collaboration revenue rose 30% to $1.18 billion on higher Dupixent sales, which grew 19% globally to $3.67 billion.

The quarter also brought mixed regulatory news. Dupixent was approved in the U.S. for chronic spontaneous urticaria, and EYLEA HD received a Complete Response Letter for its pre-filled syringe, tied to a third-party component supplier, and a separate CRL limiting extended dosing intervals to no longer than every 16 weeks. Management kept full-year 2025 R&D and SG&A guidance unchanged, lowered GAAP and non-GAAP gross margin guidance, and narrowed capital expenditure guidance.

Capital returns continued with $1.05 billion^c in Q1 buybacks, $3.87 billion of remaining authorization, and a first-time $0.88 per share dividend declared for June payment. For investors, the key issues are whether EYLEA HD growth can offset legacy erosion, the timing of the EYLEA HD syringe and dosing resubmissions, gross margin pressure from inventory write-offs, and the cadence of pipeline readouts expected later in 2025.

02—Key points

Key Highlights

Q1 2025 total revenues were $3.03 billion, down 4% year over year, while GAAP diluted EPS rose 16% to $7.27 and non-GAAP diluted EPS fell 14% to $8.22.
Combined EYLEA HD and EYLEA U.S. net sales declined 26% to $1.04 billion, with legacy EYLEA down 39% and EYLEA HD up 54% to $307 million.
Sanofi collaboration revenue increased 30% to $1.18 billion, driven by a 19% rise in global Dupixent sales to $3.67 billion.
The FDA issued a CRL for the EYLEA HD pre-filled syringe (April 23, 2025), attributed to a question for a third-party component supplier, and a separate CRL limited extended dosing to intervals no longer than every 16 weeks.
Full-year 2025 gross margin on net product sales guidance was lowered to 83%–84% GAAP and 86%–87% non-GAAP, and capex guidance was narrowed to $850–$950 million.
Regeneron repurchased $1.05 billion of stock in Q1 2025, leaving $3.87 billion available, and declared its first quarterly cash dividend of $0.88 per share.
Several regulatory decisions are scheduled for mid-to-late 2025, including Dupixent in bullous pemphigoid (June 20), linvoseltamab in R/R multiple myeloma (July 10), odronextamab in R/R follicular lymphoma (July 30), and EYLEA HD for RVO and monthly dosing (August 19).

03—Questions

Frequently Asked Questions

Why did Regeneron's total revenue decline despite strong Dupixent growth?
The decline was driven by EYLEA. Combined EYLEA HD and EYLEA U.S. net sales fell 26% to $1.04 billion because legacy EYLEA lost volume to biosimilars and compounded bevacizumab, patients transitioned to EYLEA HD, and net selling prices fell. Wholesaler inventory was also lower at quarter end. Sanofi collaboration revenue rose 30%, but this did not fully offset the EYLEA decline, leaving total revenue down 4%.
Why did non-GAAP EPS fall while GAAP EPS rose?
GAAP net income benefited from a $140 million net unrealized gain on equity securities, compared with a $196 million unrealized loss in Q1 2024. Non-GAAP results exclude these investment gains, so the swing from a year-earlier loss to a gain boosted GAAP earnings while non-GAAP earnings declined 17% in net income terms, from $1.12 billion to $928 million.
How serious are the FDA setbacks for EYLEA HD?
The pre-filled syringe CRL reportedly did not raise safety, efficacy, device usability, labeling, or pre-approval inspection concerns, and management believes the key issue involves a third-party component supplier that is responding quickly. The extended dosing CRL is more limiting, since the FDA said the data do not support intervals beyond every 16 weeks, and management is still evaluating that decision. Investors should watch resubmission timing and whether the monthly dosing and RVO sBLA, with an August 19, 2025 target action date, proceeds on schedule.
What is Regeneron's capital allocation strategy?
Management is prioritizing internal R&D and commercial investment, opportunistic share repurchases, and a dividend that was initiated in 2025. Q1 buybacks totaled $1.05 billion, with $3.87 billion remaining under authorizations as of March 31, 2025. The company also announced more than $7 billion in New York and North Carolina infrastructure and manufacturing investments, including a 10-year Fujifilm agreement expected to nearly double its large-scale U.S. manufacturing capacity.
What should investors watch for the rest of 2025?
Key catalysts include the June 20 Dupixent bullous pemphigoid action date, the July 10 linvoseltamab and July 30 odronextamab decisions, the August 19 EYLEA HD RVO and monthly dosing decision, and resolution of the EYLEA HD pre-filled syringe CRL. Management also expects pivotal or proof-of-concept data across immunology, oncology, hematology, internal medicine, and rare diseases later in 2025. Gross margin pressure from inventory write-offs and the lower guidance range are also important to monitor.

04—Continue

← View all 8-K filings